相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study
O. Nemoto et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis A Randomized Clinical Trial
Tadashi Terui et al.
JAMA DERMATOLOGY (2018)
Efficacy and safety of guselkumab, an anti-IL23 Monoclonal antibody, in patients with active psoriatic arthritis: A phase 2a, randomized, double-blind, placebo-controlled study
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey
Mark G. Lebwohl et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2016)
Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation
Joseph R. Maxwell et al.
IMMUNITY (2015)
Clinical improvement in psoriasis with specific targeting of interleukin-23
Tamara Kopp et al.
NATURE (2015)
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database
Kiyoshi Kubota et al.
BMJ OPEN (2015)
Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
Howard Sofen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
A New Player on the Psoriasis Block: IL-17A-and IL-22-Producing Innate Lymphoid Cells
Nicole L. Ward et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR+ ILC3 in Lesional Skin and Blood of Psoriasis Patients
Marcel B. M. Teunissen et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Characterization of Innate Lymphoid Cells in Human Skin and Blood Demonstrates Increase of NKp44+ILC3 in Psoriasis
Federica Villanova et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2014)
Secukinumab in Plaque Psoriasis - Results of Two Phase 3 Trials
Richard G. Langley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cytokine Requirements for the Differentiation and Expansion of IL-17A-and IL-22-Producing Human Vγ2Vδ2 T Cells
Kristin J. Ness-Schwickerath et al.
JOURNAL OF IMMUNOLOGY (2010)
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Alan Menter et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Development, cytokine profile and function of human interleukin 17-producing helper T cells
Nicholas J. Wilson et al.
NATURE IMMUNOLOGY (2007)
Psoriasis 1 - Pathogenesis and clinical features of psoriasis
Christopher E. M. Griffiths et al.
LANCET (2007)
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial
K Reich et al.
LANCET (2005)
A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction
KA Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17
S Aggarwal et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
分享论文
